ORTERONEL (TAK-700) is a compound that has entered Phase III clinical trials for the treatment of castration-resistant prostate cancer.

• Product NameORTERONEL (TAK-700) is a compound that has entered Phase III clinical trials for the treatment of castration-resistant prostate cancer.
• CAS
• MF
• MW0
• EINECS
• MOL FileMol File